Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 59

1.

Gut-associated IgA+ immune cells regulate obesity-related insulin resistance.

Luck H, Khan S, Kim JH, Copeland JK, Revelo XS, Tsai S, Chakraborty M, Cheng K, Tao Chan Y, Nøhr MK, Clemente-Casares X, Perry MC, Ghazarian M, Lei H, Lin YH, Coburn B, Okrainec A, Jackson T, Poutanen S, Gaisano H, Allard JP, Guttman DS, Conner ME, Winer S, Winer DA.

Nat Commun. 2019 Aug 13;10(1):3650. doi: 10.1038/s41467-019-11370-y.

2.

Aryl hydrocarbon receptor agonist indigo protects against obesity-related insulin resistance through modulation of intestinal and metabolic tissue immunity.

Lin YH, Luck H, Khan S, Schneeberger PHH, Tsai S, Clemente-Casares X, Lei H, Leu YL, Chan YT, Chen HY, Yang SH, Coburn B, Winer S, Winer DA.

Int J Obes (Lond). 2019 Apr 3. doi: 10.1038/s41366-019-0340-1. [Epub ahead of print]

PMID:
30944419
3.

Gut T Cells Feast on GLP-1 to Modulate Cardiometabolic Disease.

Tsai S, Winer S, Winer DA.

Cell Metab. 2019 Apr 2;29(4):787-789. doi: 10.1016/j.cmet.2019.03.002.

PMID:
30943389
4.

Insulin Receptor-Mediated Stimulation Boosts T Cell Immunity during Inflammation and Infection.

Tsai S, Clemente-Casares X, Zhou AC, Lei H, Ahn JJ, Chan YT, Choi O, Luck H, Woo M, Dunn SE, Engleman EG, Watts TH, Winer S, Winer DA.

Cell Metab. 2018 Dec 4;28(6):922-934.e4. doi: 10.1016/j.cmet.2018.08.003. Epub 2018 Aug 30.

PMID:
30174303
5.

Pseudomelanosis Duodeni and Duodenal Polyp.

Shimamura Y, Akram H, Winer S, Marcon N.

Intern Med. 2018 Apr 1;57(7):1049-1050. doi: 10.2169/internalmedicine.9733-17. Epub 2017 Dec 8. No abstract available.

6.

Type I Interferon Responses Drive Intrahepatic T cells to Promote Metabolic Syndrome.

Ghazarian M, Revelo XS, Nøhr MK, Luck H, Zeng K, Lei H, Tsai S, Schroer SA, Park YJ, Chng MHY, Shen L, D'Angelo JA, Horton P, Chapman WC, Brockmeier D, Woo M, Engleman EG, Adeyi O, Hirano N, Jin T, Gehring AJ, Winer S, Winer DA.

Sci Immunol. 2017 Apr 21;2(10). pii: eaai7616. doi: 10.1126/sciimmunol.aai7616.

7.

Immunologic impact of the intestine in metabolic disease.

Winer DA, Winer S, Dranse HJ, Lam TK.

J Clin Invest. 2017 Jan 3;127(1):33-42. doi: 10.1172/JCI88879. Epub 2017 Jan 3. Review.

8.

A Schwannoma of the Distal Esophagus.

Shimamura Y, Winer S, Marcon N.

Clin Gastroenterol Hepatol. 2016 Nov;14(11):A19-A20. doi: 10.1016/j.cgh.2016.07.023. Epub 2016 Jul 27. No abstract available.

PMID:
27475621
9.

A Giant Circumferential Inlet Patch With Acid Secretion Causing Stricture.

Shimamura Y, Winer S, Marcon N.

Clin Gastroenterol Hepatol. 2017 Apr;15(4):A22-A23. doi: 10.1016/j.cgh.2016.10.004. Epub 2016 Oct 8. No abstract available.

PMID:
27729241
10.

Nucleic Acid-Targeting Pathways Promote Inflammation in Obesity-Related Insulin Resistance.

Revelo XS, Ghazarian M, Chng MH, Luck H, Kim JH, Zeng K, Shi SY, Tsai S, Lei H, Kenkel J, Liu CL, Tangsombatvisit S, Tsui H, Sima C, Xiao C, Shen L, Li X, Jin T, Lewis GF, Woo M, Utz PJ, Glogauer M, Engleman E, Winer S, Winer DA.

Cell Rep. 2016 Jul 19;16(3):717-30. doi: 10.1016/j.celrep.2016.06.024. Epub 2016 Jun 30.

11.

Starving Intestinal Inflammation with the Amino Acid Sensor GCN2.

Revelo XS, Winer S, Winer DA.

Cell Metab. 2016 May 10;23(5):763-5. doi: 10.1016/j.cmet.2016.04.020.

12.

NLRX1 Acts as an Epithelial-Intrinsic Tumor Suppressor through the Modulation of TNF-Mediated Proliferation.

Tattoli I, Killackey SA, Foerster EG, Molinaro R, Maisonneuve C, Rahman MA, Winer S, Winer DA, Streutker CJ, Philpott DJ, Girardin SE.

Cell Rep. 2016 Mar 22;14(11):2576-86. doi: 10.1016/j.celrep.2016.02.065. Epub 2016 Mar 10.

13.

The Intestinal Immune System in Obesity and Insulin Resistance.

Winer DA, Luck H, Tsai S, Winer S.

Cell Metab. 2016 Mar 8;23(3):413-26. doi: 10.1016/j.cmet.2016.01.003. Epub 2016 Feb 4. Review.

14.

Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE): Determining Therapeutic Goals for Treat-to-Target.

Peyrin-Biroulet L, Sandborn W, Sands BE, Reinisch W, Bemelman W, Bryant RV, D'Haens G, Dotan I, Dubinsky M, Feagan B, Fiorino G, Gearry R, Krishnareddy S, Lakatos PL, Loftus EV Jr, Marteau P, Munkholm P, Murdoch TB, Ordás I, Panaccione R, Riddell RH, Ruel J, Rubin DT, Samaan M, Siegel CA, Silverberg MS, Stoker J, Schreiber S, Travis S, Van Assche G, Danese S, Panes J, Bouguen G, O'Donnell S, Pariente B, Winer S, Hanauer S, Colombel JF.

Am J Gastroenterol. 2015 Sep;110(9):1324-38. doi: 10.1038/ajg.2015.233. Epub 2015 Aug 25. Review.

PMID:
26303131
15.

Immunopathology of Adipose Tissue during Metabolic Syndrome.

Ghazarian M, Luck H, Revelo XS, Winer S, Winer DA.

Turk Patoloji Derg. 2015;31 Suppl 1:172-80. doi: 10.5146/tjpath.2015.01323. Review.

16.

Are obesity-related insulin resistance and type 2 diabetes autoimmune diseases?

Tsai S, Clemente-Casares X, Revelo XS, Winer S, Winer DA.

Diabetes. 2015 Jun;64(6):1886-97. doi: 10.2337/db14-1488. Review.

17.

Regulation of obesity-related insulin resistance with gut anti-inflammatory agents.

Luck H, Tsai S, Chung J, Clemente-Casares X, Ghazarian M, Revelo XS, Lei H, Luk CT, Shi SY, Surendra A, Copeland JK, Ahn J, Prescott D, Rasmussen BA, Chng MH, Engleman EG, Girardin SE, Lam TK, Croitoru K, Dunn S, Philpott DJ, Guttman DS, Woo M, Winer S, Winer DA.

Cell Metab. 2015 Apr 7;21(4):527-42. doi: 10.1016/j.cmet.2015.03.001.

18.

Response to Villanacci et. al.

Bryant RV, Winer S, Travis SP, Riddell RH.

J Crohns Colitis. 2015 May;9(5):429. doi: 10.1093/ecco-jcc/jjv046. Epub 2015 Mar 11. No abstract available.

PMID:
25761770
19.

Systematic review: histological remission in inflammatory bowel disease. Is 'complete' remission the new treatment paradigm? An IOIBD initiative.

Bryant RV, Winer S, Travis SP, Riddell RH.

J Crohns Colitis. 2014 Dec;8(12):1582-97. doi: 10.1016/j.crohns.2014.08.011. Epub 2014 Sep 27. Review.

20.

Perforin is a novel immune regulator of obesity-related insulin resistance.

Revelo XS, Tsai S, Lei H, Luck H, Ghazarian M, Tsui H, Shi SY, Schroer S, Luk CT, Lin GH, Mak TW, Woo M, Winer S, Winer DA.

Diabetes. 2015 Jan;64(1):90-103. doi: 10.2337/db13-1524. Epub 2014 Jul 21.

21.

The mitochondrial protein NLRX1 controls the balance between extrinsic and intrinsic apoptosis.

Soares F, Tattoli I, Rahman MA, Robertson SJ, Belcheva A, Liu D, Streutker C, Winer S, Winer DA, Martin A, Philpott DJ, Arnoult D, Girardin SE.

J Biol Chem. 2014 Jul 11;289(28):19317-30. doi: 10.1074/jbc.M114.550111. Epub 2014 May 27.

22.

Morphological and inflammatory changes in visceral adipose tissue during obesity.

Revelo XS, Luck H, Winer S, Winer DA.

Endocr Pathol. 2014 Mar;25(1):93-101. doi: 10.1007/s12022-013-9288-1. Review.

PMID:
24356782
23.

B Lymphocytes in obesity-related adipose tissue inflammation and insulin resistance.

Winer DA, Winer S, Chng MH, Shen L, Engleman EG.

Cell Mol Life Sci. 2014 Mar;71(6):1033-43. doi: 10.1007/s00018-013-1486-y. Epub 2013 Oct 15. Review.

24.

TRPV1 gates tissue access and sustains pathogenicity in autoimmune encephalitis.

Paltser G, Liu XJ, Yantha J, Winer S, Tsui H, Wu P, Maezawa Y, Cahill LS, Laliberté CL, Ramagopalan SV, DeLuca GC, Sadovnick AD, Astsaturov I, Ebers GC, Henkelman RM, Salter MW, Dosch HM.

Mol Med. 2013 Jul 24;19:149-59. doi: 10.2119/molmed.2012.00329.

25.

Effect of hormone therapy on breast epithelial cell proliferation.

Stanczyk FZ, Winer SA.

Menopause. 2013 May;20(5):483-5. doi: 10.1097/GME.0b013e31828ebfb6. No abstract available.

PMID:
23615638
26.

Interleukin-17 in post-stroke neurodegeneration.

Swardfager W, Winer DA, Herrmann N, Winer S, Lanctôt KL.

Neurosci Biobehav Rev. 2013 Mar;37(3):436-47. doi: 10.1016/j.neubiorev.2013.01.021. Epub 2013 Jan 28. Review.

PMID:
23370232
27.

Progestogens used in postmenopausal hormone therapy: differences in their pharmacological properties, intracellular actions, and clinical effects.

Stanczyk FZ, Hapgood JP, Winer S, Mishell DR Jr.

Endocr Rev. 2013 Apr;34(2):171-208. doi: 10.1210/er.2012-1008. Epub 2012 Dec 13. Review.

28.

Inhibition of peptidyl-arginine deiminases reverses protein-hypercitrullination and disease in mouse models of multiple sclerosis.

Moscarello MA, Lei H, Mastronardi FG, Winer S, Tsui H, Li Z, Ackerley C, Zhang L, Raijmakers R, Wood DD.

Dis Model Mech. 2013 Mar;6(2):467-78. doi: 10.1242/dmm.010520. Epub 2012 Nov 1.

29.

Villous papillary thyroid carcinoma: a variant associated with marfan syndrome.

Winer DA, Winer S, Rotstein L, Asa SL, Mete O.

Endocr Pathol. 2012 Dec;23(4):254-9. doi: 10.1007/s12022-012-9219-6.

PMID:
22847364
30.

B lymphocytes as emerging mediators of insulin resistance.

Winer DA, Winer S, Shen L, Chng MH, Engleman EG.

Int J Obes Suppl. 2012 Jul;2(Suppl 1):S4-S7.

31.

The adaptive immune system as a fundamental regulator of adipose tissue inflammation and insulin resistance.

Winer S, Winer DA.

Immunol Cell Biol. 2012 Sep;90(8):755-62. doi: 10.1038/icb.2011.110. Epub 2012 Jan 10. Review.

PMID:
22231651
32.

B cells promote insulin resistance through modulation of T cells and production of pathogenic IgG antibodies.

Winer DA, Winer S, Shen L, Wadia PP, Yantha J, Paltser G, Tsui H, Wu P, Davidson MG, Alonso MN, Leong HX, Glassford A, Caimol M, Kenkel JA, Tedder TF, McLaughlin T, Miklos DB, Dosch HM, Engleman EG.

Nat Med. 2011 May;17(5):610-7. doi: 10.1038/nm.2353. Epub 2011 Apr 17.

33.

Unexpected acceleration of type 1 diabetes by transgenic expression of B7-H1 in NOD mouse peri-islet glia.

Yantha J, Tsui H, Winer S, Song A, Wu P, Paltser G, Ellis J, Dosch HM.

Diabetes. 2010 Oct;59(10):2588-96. doi: 10.2337/db09-1209. Epub 2010 Jun 3.

34.

Obesity predisposes to Th17 bias.

Winer S, Paltser G, Chan Y, Tsui H, Engleman E, Winer D, Dosch HM.

Eur J Immunol. 2009 Sep;39(9):2629-35. doi: 10.1002/eji.200838893.

35.

Normalization of obesity-associated insulin resistance through immunotherapy.

Winer S, Chan Y, Paltser G, Truong D, Tsui H, Bahrami J, Dorfman R, Wang Y, Zielenski J, Mastronardi F, Maezawa Y, Drucker DJ, Engleman E, Winer D, Dosch HM.

Nat Med. 2009 Aug;15(8):921-9. doi: 10.1038/nm.2001. Epub 2009 Jul 26.

36.

Premenstrual syndrome and premenstrual dysphoric disorder: quality of life and burden of illness.

Rapkin AJ, Winer SA.

Expert Rev Pharmacoecon Outcomes Res. 2009 Apr;9(2):157-70. doi: 10.1586/erp.09.14. Review.

PMID:
19402804
37.

Islet glia, neurons, and beta cells.

Tsui H, Winer S, Chan Y, Truong D, Tang L, Yantha J, Paltser G, Dosch HM.

Ann N Y Acad Sci. 2008 Dec;1150:32-42. doi: 10.1196/annals.1447.033. Review.

PMID:
19120264
38.

Drospirenone/ethinyl estradiol.

Rapkin AJ, Sorger SN, Winer SA.

Drugs Today (Barc). 2008 Feb;44(2):133-45. doi: 10.1358/dot.2008.44.2.1191057. Review.

PMID:
18389090
39.

The pharmacologic management of premenstrual dysphoric disorder.

Rapkin AJ, Winer SA.

Expert Opin Pharmacother. 2008 Feb;9(3):429-45. doi: 10.1517/14656566.9.3.429 . Review.

PMID:
18220493
40.

Targeting of pancreatic glia in type 1 diabetes.

Tsui H, Chan Y, Tang L, Winer S, Cheung RK, Paltser G, Selvanantham T, Elford AR, Ellis JR, Becker DJ, Ohashi PS, Dosch HM.

Diabetes. 2008 Apr;57(4):918-28. doi: 10.2337/db07-0226. Epub 2008 Jan 15.

41.

Ethinyl estradiol/drospirenone for the treatment of the emotional and physical symptoms of premenstrual dysphoric disorder.

Rapkin AJ, McDonald M, Winer SA.

Womens Health (Lond). 2007 Jul;3(4):395-408. doi: 10.2217/17455057.3.4.395.

PMID:
19804014
42.

Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases.

Mastronardi FG, Tsui H, Winer S, Wood DD, Selvanantham T, Galligan C, Fish EN, Dosch HM, Moscarello MA.

Mult Scler. 2007 Jun;13(5):596-609. Epub 2007 Feb 9.

PMID:
17548438
43.

Drospirenone: a novel progestin.

Rapkin AJ, Winer SA.

Expert Opin Pharmacother. 2007 May;8(7):989-99. Review.

PMID:
17472544
44.

Premenstrual disorders: prevalence, etiology and impact.

Winer SA, Rapkin AJ.

J Reprod Med. 2006 Apr;51(4 Suppl):339-47. Review.

PMID:
16734317
45.
46.

Neuronal elements in the pathogenesis of type 1 diabetes.

Tsui H, Winer S, Jakowsky G, Dosch HM.

Rev Endocr Metab Disord. 2003 Sep;4(3):301-10. Review. No abstract available.

PMID:
14501181
47.

Deviation of islet autoreactivity to cryptic epitopes protects NOD mice from diabetes.

Song A, Winer S, Tsui H, Sampson A, Pasceri P, Ellis J, Elliott JF, Dosch HM.

Eur J Immunol. 2003 Feb;33(2):546-55.

48.

Autoimmune islet destruction in spontaneous type 1 diabetes is not beta-cell exclusive.

Winer S, Tsui H, Lau A, Song A, Li X, Cheung RK, Sampson A, Afifiyan F, Elford A, Jackowski G, Becker DJ, Santamaria P, Ohashi P, Dosch HM.

Nat Med. 2003 Feb;9(2):198-205. Epub 2003 Jan 21.

PMID:
12539039
49.

Primary Sjögren's syndrome and deficiency of ICA69.

Winer S, Astsaturov I, Cheung R, Tsui H, Song A, Gaedigk R, Winer D, Sampson A, McKerlie C, Bookman A, Dosch HM.

Lancet. 2002 Oct 5;360(9339):1063-9.

PMID:
12383988
50.

ICA69(null) nonobese diabetic mice develop diabetes, but resist disease acceleration by cyclophosphamide.

Winer S, Astsaturov I, Gaedigk R, Hammond-McKibben D, Pilon M, Song A, Kubiak V, Karges W, Arpaia E, McKerlie C, Zucker P, Singh B, Dosch HM.

J Immunol. 2002 Jan 1;168(1):475-82.

Supplemental Content

Support Center